| Literature DB >> 26028998 |
David M Albala1, Jerome B Riebman2, Richard Kocharian2, Bogdan Ilie2, John Albanese2, Jessica Shen2, Liza Ovington2, Jonathan Batiller2.
Abstract
In the United States, fibrin sealants have been used to achieve hemostasis for nearly two decades. Although their clinical utility was first demonstrated in cardiac surgery, their effectiveness and safety have since been demonstrated to extend to a wide array of procedures. Fibrin sealants typically contain two components-fibrinogen and thrombin-that are combined and delivered simultaneously to a target bleeding site in order to achieve hemostasis. However, many commercial formulations contain other additional components, such as antifibrinolytic agents, that have been associated with adverse outcomes. This subanalysis compares the safety and effectiveness of a fibrin sealant versus an absorbable hemostat for achieving hemostasis during urologic procedures with mild to moderate bleeding.Entities:
Keywords: Fibrin tissue adhesive; Hemostasis; Hemostatics; Surgical technique; Urologic surgical procedures
Year: 2015 PMID: 26028998 PMCID: PMC4444771
Source DB: PubMed Journal: Rev Urol ISSN: 1523-6161